Group 1 - The core focus of Telix Pharmaceuticals Ltd. is on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [1] - A class action has been filed on behalf of all investors who purchased or acquired Telix securities during the class period from February 21, 2025, to August 28, 2025 [1]

Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [2] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [2] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [2] Financial Results Announcement - Telix will release its financial results for the half-year ended 30 June 2025 on Thursday, 21 August 2025 [1] - An investor webcast and conference call is scheduled for 9.30 am AEST on the same day [1] - Participants can register for the webcast and teleconference through provided links [1]